Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 489 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ophthalmic Surgery Clear all

Conditions: Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataract
Interventions: Mapracorat, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cataract
Interventions: Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 1,342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Yutiq 0.18 MG Drug Implant; Drug
Lead sponsor: Sanjay Asrani; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cataract
Interventions: Lenstar Biometer; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Inflammatory Reaction Due to Ocular Lens Prosthesis
Interventions: IBI-10090; Drug
Lead sponsor: ICON Bioscience Inc; Industry
Eligibility: 40 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Glaucoma Eye, Ahmed Glaucoma Valve Implantation
Interventions: Standard Implantation, Tied off Tube; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ectasia
Interventions: riboflavin ophthalmic solution, UVA Irradiation; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 14 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 10
States / cities: La Jolla, California • San Diego, California • Miami, Florida + 7 more

Conditions: Keratoconus, Corneal Ectasia
Interventions: KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution; Device · Drug
Lead sponsor: American-European Congress of Ophthalmic Surgery; Network
Eligibility: 12 Years and older
Enrollment: 1,721 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more

Conditions: Refractive Errors
Interventions: AccuraSee IOPCL with +3.0D add; Device
Lead sponsor: OnPoint Vision Inc; Industry
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Eye Disorders, Cataract Extraction, Cataract and IOL Surgery, Cataract Surgery Experience, Cataract Surgery, Intraocular Lens
Interventions: LLM-based Education; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cataracts
Interventions: Femtosecond Laser; Procedure
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Goodlettsville, Tennessee

Conditions: Astigmatism, Cataract
Interventions: Femtosecond laser assisted cataract surgery with astigmatism management; Procedure
Lead sponsor: Kenneth J Rosenthal; Other
Eligibility: 18 Years to 95 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Intraocular Melanoma
Interventions: nab-paclitaxel; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions: Pembrolizumab, Stereotactic Radiosurgery; Biological · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cataracts
Interventions: Galilei dual Scheimpflug analyzer; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 40 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions: Minimally Invasive Micro Sclerostomy Device; Device
Lead sponsor: Sanoculis Ltd; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain, Inflammation, Cataract
Interventions: Bromfenac Ophthalmic Solution, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye Disease, Meibomian Gland Dysfunction, Cataract Senile, Dry Eye Syndromes
Interventions: Systane iLux Treatment; Device
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 79 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
Interventions: Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 15
States / cities: Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more

Conditions: Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
Interventions: Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study; Biological · Other · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 13
States / cities: San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more

Search by objective public record fields.

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Nepafenac 0.3% Two Study

A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery

Medications Effect on Lenstar Measurements

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Tied Tube Trial in Glaucoma Surgery

Corneal Collagen Cross-Linking for Ectasia (CXL)

Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Early Feasibility Study to Evaluate the AccuraSee in Correcting Residual Refractive Errors After Cataract Surgery

Effectiveness of a Large Language Model-Based Educational Tool on Intraocular Lens Options

Laser Cataract Surgery With the Femtosecond Laser Technology

Astigmatism Management With Iris-registration Guided Corneal Relaxing Incisions or Toric IOLs During Cataract Surgery

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

PIONEER: Intraoperative and Perioperative OCT Study

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Accuracy of the Galilei Analyzer to Calculate the Effective Corneal Power After Corneal Refractive Surgery

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery